Literature DB >> 21292987

Toll in the vessel wall--for better or worse?

Göran K Hansson1, Anna M Lundberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21292987      PMCID： PMC3041064          DOI： 10.1073/pnas.1019722108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  17 in total

Review 1.  Inflammation, atherosclerosis, and coronary artery disease.

Authors:  Göran K Hansson
Journal:  N Engl J Med       Date:  2005-04-21       Impact factor: 91.245

2.  Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation.

Authors:  Kristina Edfeldt; Jesper Swedenborg; Göran K Hansson; Zhong-qun Yan
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

3.  Modulation of atherosclerosis in mice by Toll-like receptor 2.

Authors:  Adam E Mullick; Peter S Tobias; Linda K Curtiss
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

4.  Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells.

Authors:  Xin Yang; Vanishree Murthy; Kelly Schultz; Jeffrey B Tatro; Katherine A Fitzgerald; Debbie Beasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-06-16       Impact factor: 4.733

Review 5.  Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics.

Authors:  Jean-Laurent Casanova; Laurent Abel; Lluis Quintana-Murci
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

6.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

7.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.

Authors:  Kathrin S Michelsen; Michelle H Wong; Prediman K Shah; Wenxuan Zhang; Juliana Yano; Terence M Doherty; Shizuo Akira; Tripathi B Rajavashisth; Moshe Arditi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

8.  mRNA is an endogenous ligand for Toll-like receptor 3.

Authors:  Katalin Karikó; Houping Ni; John Capodici; Marc Lamphier; Drew Weissman
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

9.  Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism.

Authors:  Antonio Castrillo; Sean B Joseph; Sagar A Vaidya; Margaret Haberland; Alan M Fogelman; Genhong Cheng; Peter Tontonoz
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

10.  Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems.

Authors:  Anna M Lundberg; Stefan K Drexler; Claudia Monaco; Lynn M Williams; Sandra M Sacre; Marc Feldmann; Brian M Foxwell
Journal:  Blood       Date:  2007-07-27       Impact factor: 22.113
View more
  3 in total

1.  Activation of Toll-like receptor 3 increases mouse aortic vascular smooth muscle cell contractility through ERK1/2 pathway.

Authors:  Trevor Hardigan; Kathryn Spitler; Takayuki Matsumoto; Maria Alicia Carrillo-Sepulveda
Journal:  Pflugers Arch       Date:  2015-03-01       Impact factor: 3.657

2.  Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion.

Authors:  Katyayni Vinnakota; Feng Hu; Min-Chi Ku; Petya B Georgieva; Frank Szulzewsky; Andreas Pohlmann; Sonia Waiczies; Helmar Waiczies; Thoralf Niendorf; Seija Lehnardt; Uwe-Karsten Hanisch; Michael Synowitz; Darko Markovic; Susanne A Wolf; Rainer Glass; Helmut Kettenmann
Journal:  Neuro Oncol       Date:  2013-09-05       Impact factor: 12.300

3.  Control of dichotomic innate and adaptive immune responses by artery tertiary lymphoid organs in atherosclerosis.

Authors:  Falk Weih; Rolf Gräbner; Desheng Hu; Michael Beer; Andreas J R Habenicht
Journal:  Front Physiol       Date:  2012-07-06       Impact factor: 4.566
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.